A California legislative measure, AB 2697, which proposes to authorize licensed cannabis retailers and microbusinesses to operate drive-thru windows, has advanced to a floor vote in the state Assembly. The bill, which cleared the Assembly Appropriations Committee with a 13-1 vote on Wednesday, permits licensed storefronts to sell cannabis products “to a customer in a motor vehicle in a drive-through located on the premises.” This initiative seeks to establish according to Marijuana Moment, a new pathway for patient and consumer access, specifically for California medical cannabis drive-thrus.
Regulatory Rationale and Market Competition
Authored by Assemblymember Gail Pellerin (D), AB 2697 had previously received approval from the Assembly Business and Professions Committee. The legislation stipulates that cannabis businesses would require local jurisdictional approval to implement the drive-thru option. Assemblymember Jessica Caloza (D) stated before the recent vote that the bill addresses a “regulatory inconsistency” where licensed cannabis retailers can offer curbside pickup, a practice adapted during the COVID-19 pandemic, but are generally prohibited from fulfilling orders via a drive-thru window.
Caloza indicated that the legislation aims to make legal cannabis more accessible, thereby assisting the regulated market in competing with the illicit market. This regulatory adjustment is presented as a practical solution to streamline operations for licensed entities.
Enhancing Patient Access Through Drive-Thrus
The proposed expansion of access through California medical cannabis drive-thrus is particularly highlighted for its potential benefits to specific patient populations. Mark Smith, representing Chuck’s Wellness Center, a retailer in Placerville, emphasized that the bill is fundamentally “about improving access.”
- Smith noted that a significant portion of customers rely on cannabis for medical purposes.
- This includes seniors, veterans, and individuals with chronic conditions that impact mobility.
- For many, navigating a retail space can present physical difficulties.
- A drive-thru model would address this barrier in a controlled, compliant manner, supporting Americans With Disabilities Act (ADA)-conscious principles and fostering a more inclusive retail environment.
The argument is that this change would not alter who has access to medical cannabis, but rather how that access is facilitated, making it easier for those with physical limitations.
Economic Implications for the Cannabis Industry
Beyond patient access, the bill also carries economic considerations for the state’s cannabis sector. Amy O’Gorman Jenkins of the California Cannabis Operators Association stated that the proposal “supports the fiscal interests of the state at a time when you see cannabis revenues in sharp decline.” She underscored the importance of offering practical solutions to retain consumers within regulated stores.
Legislative Progress and Broader Policy Context
Following its passage through the Assembly Appropriations Committee, AB 2697 is now scheduled for an Assembly floor vote. If approved, it will then proceed to the Senate for consideration. This legislative effort is part of a broader series of policy adjustments within California’s cannabis framework.
Recent regulatory changes in the state include modifications to the cannabis licensing process, intended to align with federal rescheduling discussions. Additionally, Governor Gavin Newsom signed a bill earlier that month aimed at streamlining research on cannabis and psychedelics. In September, the governor also enacted a measure to temporarily halt a previously implemented tax increase on cannabis products. California officials have also awarded nearly $30 million in grants for academic research projects focused on cannabis, indicating continued state engagement with the sector’s development.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Hemp Gazette does not provide medical recommendations, diagnoses, or treatment plans. Always consult a qualified healthcare practitioner before making any decisions regarding your health or any medical condition. Statements concerning the therapeutic uses of hemp, cannabis, or cannabinoid-derived products have not been evaluated by Australia’s Therapeutic Goods Administration (TGA). Medicinal cannabis products in Australia are accessed via prescription pathways under TGA regulation.
